These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25132340)

  • 21. Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
    Fougere RJ; Currie KD; Nigro MK; Stothers L; Rapoport D; Krassioukov AV
    J Neurotrauma; 2016 Sep; 33(18):1651-7. PubMed ID: 26980078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
    Giannantoni A; Gubbiotti M; Rubilotta E; Balzarro M; Antonelli A; Bini V
    Minerva Urol Nephrol; 2022 Oct; 74(5):625-635. PubMed ID: 33769020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury.
    Chen SF; Jiang YH; Jhang JF; Kuo HC
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
    Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
    Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
    Álvares RA; Araújo ID; Sanches MD
    BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
    Linsenmeyer TA
    J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
    Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
    Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
    Soljanik I
    Drugs; 2013 Jul; 73(10):1055-66. PubMed ID: 23775527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
    Huynh Le Maux A; Pignol B; Behr-Roussel D; Blachon JL; Chabrier PE; Compagnie S; Picaut P; Bernabé J; Giuliano F; Denys P
    Toxins (Basel); 2015 Dec; 7(12):5462-71. PubMed ID: 26694464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
    Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
    Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections].
    Karsenty G; Corcos J; Schurch B; Ruffion A; Chartier-Kastler E
    Prog Urol; 2007 May; 17(3):568-75. PubMed ID: 17622092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?
    Aharony S; Przydacz M; Van Ba OL; Corcos J
    Neurourol Urodyn; 2020 Jan; 39(1):203-210. PubMed ID: 31578763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.